伊马替尼（STI571）治疗费城染色体阳性白血病的皮肤不良反应：54例患者的前瞻性研究
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
作者信息
Valeyrie Laurence, Bastuji-Garin Sylvie, Revuz Jean, Bachot Nicolas, Wechsler Janine, Berthaud Patrice, Tulliez Michel, Giraudier Stéphane
机构信息
Department of Dermatology, Henri-Mondor Hospital (Assistance Publique Hopitaux de Paris), Paris XII University, F-94010 Paris Cedex, France.
出版信息
J Am Acad Dermatol. 2003 Feb;48(2):201-6. doi: 10.1067/mjd.2003.44.
BACKGROUND
Imatinib is a new major treatment in chronic myeloid leukemia.
OBJECTIVE
To study the cutaneous reactions induced by imatinib.
METHODS
All inpatients and outpatients with Philadelphia chromosome-positive leukemia treated by imatinib were included in this prospective study. Clinical features, pathologic findings, evolution of each case, and analysis of potential risk factors were recorded.
RESULTS
A total of 54 patients were included, 48 of whom experienced at least 1 cutaneous reaction. These reactions consisted of 36 rashes, 35 edemas, and 22 pruritus. The rash was severe in 5 patients, resulting in temporary interruption of treatment in 3. Highly significant relationships were observed between the daily dose of imatinib and both rashes and edema. In a multivariate analysis, female sex and the daily dose of imatinib were independent risk factors for the development of rashes.
CONCLUSION
Adverse cutaneous reactions induced by imatinib are frequent, generally moderate, and dose-dependent.
背景
伊马替尼是慢性髓性白血病的一种新的主要治疗药物。
目的
研究伊马替尼引起的皮肤反应。
方法
本前瞻性研究纳入了所有接受伊马替尼治疗的费城染色体阳性白血病住院患者和门诊患者。记录了每个病例的临床特征、病理结果、病情演变以及潜在危险因素分析。
结果
共纳入54例患者，其中48例至少经历过1次皮肤反应。这些反应包括36例皮疹、35例水肿和22例瘙痒。5例患者皮疹严重，3例导致治疗暂时中断。观察到伊马替尼的每日剂量与皮疹和水肿之间存在高度显著的相关性。在多变量分析中，女性和伊马替尼的每日剂量是皮疹发生的独立危险因素。
结论
伊马替尼引起的不良皮肤反应很常见，一般为中度，且与剂量相关。
Zotero 插件